Journals / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 10

Non-alcoholic fatty liver disease: A growing public health problem in Turkey

Pages
865–871
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we present studies on the burden of NAFLD and NASH, thenatural history of NAFLD, and its association with other systemic diseases conducted with Turkish populations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Non-alcoholic fatty liver disease (NAFLD) is histologically classified as either non-alcoholic fatty liver or non-alcoholic steatohepatitis(NASH).
📊
Key Findings & Data:Individuals with NASH are at significant risk of developing hepatic fibrosis, cirrhosis,hepatocellular carcinoma, and liver-related and all-cause mortality.
💡
Conclusion & Impact:In this review, we present studies on the burden of NAFLD and NASH, thenatural history of NAFLD, and its association with other systemic diseases conducted with Turkish populations.
🔬Design:Review & Systematic Survey
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Özet

Non-alcoholic fatty liver disease (NAFLD) is histologically classified as either non-alcoholic fatty liver or non-alcoholic steatohepatitis(NASH). NASH is the progressive subtype of NAFLD. Individuals with NASH are at significant risk of developing hepatic fibrosis, cirrhosis,hepatocellular carcinoma, and liver-related and all-cause mortality. NAFLD is closely associated with obesity, type 2 diabetes mellitus(T2DM), metabolic syndrome, and cardiovascular events. Its prevalence is estimated to be above 30% in Turkey; and recent studies confirm this estimate. According to these studies, the prevalence of NAFLD in Turkey is between 48.3% and 60.1%. Currently, Turkey canbe considered a risky region in terms of NAFLD burden as it is the most obese country in Europe with an obesity prevalence of 32.1% according to the 2016 World Health Organization data. Moreover, along with the increasing prevalence of obesity and T2DM in Turkey, theburden of NAFLD is estimated to increase in the upcoming decade. Despite the growing burden, we lack well-designed systemic studiesthat investigate NAFLD and its marked histological severity. In this review, we present studies on the burden of NAFLD and NASH, thenatural history of NAFLD, and its association with other systemic diseases conducted with Turkish populations.

🔖

Cite This Article

KAYA, E., YILMAZ, Y. (2019). Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 10, 865–871. https://ajindex.com/articles/408781

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Chalasani N, Younossi Z, Lavine JE, et al. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 2018
  2. [CrossRef] 2. Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Hepatology 2019
  3. [CrossRef] 3. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol 2019
  4. [CrossRef] 4. Available from: http://www.who.int/gho/ncd/risk_factors/overweight_obesity/obesity_adults/en/ Cited: 15.12.2018 5. Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol 2018
  5. [CrossRef] 6. Celebi S, Ataseven H, Mengucuk E, Deveci SH, Acık Y, Bahcecioglu İH. Epidemic features of nonalcoholic fatty liver in urban community of Elazıg. Akademik Gastroenteroloji Dergisi 2006
  6. Kasapoglu B, Turkay C, Yalcin KS, Carlioglu A, Sozen M, Koktener A. Low vitamin D levels are associated wıth increased risk for fatty liver disease among non-obese adults. Clin Med 2013
  7. [CrossRef] 8. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016
  8. [CrossRef] 9. Okur G, Karacaer Z. The prevalence of non-alcoholic fatty liver disease in healthy young persons. North Clin Istanb 2016
  9. [CrossRef] 10. Kaya E, Demir D, Alahdab YO, Yilmaz Y. Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter. Eur J Gastroenterol Hepatol 2016
  10. [CrossRef] 11. Yilmaz Y, Ergelen R, Akin H, Imeryuz N. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur J Gastroenterol Hepatol 2013
  11. [CrossRef] 12. Yilmaz Y, Yesil A, Gerin F, et al. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scand J Gastroenterol 2014
  12. [CrossRef] 13. Sezgin O, Akpinar H, Ozer B, et al. Kapadokya Kohort Çalışması: Gastroin